Research

The FDA asked how AI should be used to optimize early-phase clinical trials. We proposed a focused use case: reviewing the statistics in Bayesian dose-escalation and dose-expansion protocols, with the human reviewer in charge of every call.

How we write Statistical Analysis Plans for trials that borrow strength from data outside the randomized comparison, anchored in regulatory precedent and locked before any outcome data are examined.